US-EU Index Rebalances / Quantitative Researcher, ORTEX

Dimitris Ioannidis

US-EU Index Rebalances / Quantitative Researcher

Global Financial Data and Analytics Platform

ORTEX

ORTEX is a global financial data and analytics platform providing real-time securities lending and short interest data, index rebalance data, holdings and insider transactions, trading signals, corporate actions and news,  stock machine learning and factor scores and other analytics. The majority of the data are downloadable and accessible through APIs.

Event-Driven

<ul>
<li>
<a href="https://www.smartkarma.com/entities/koninklijke-vopak-nv" target="_blank" data-smartkarma-citation="entities:21144:1" rel="noopener">Koninklijke Vopak Nv (VPK NA)</a> &amp; <a href="https://www.smartkarma.com/entities/shaftesbury-plc" target="_blank" data-smartkarma-citation="entities:22140:1" rel="noopener">Shaftesbury PLC (SHB LN)</a> are currently passing the entry rank of SXXP. Forecasted passive fund demands are $22m-$34m and 3-5 ADV. </li>
<li>
<a href="https://www.smartkarma.com/entities/indivior-plc" target="_blank" data-smartkarma-citation="entities:21996:1" rel="noopener">Indivior PLC (INDV LN)</a> is currently the only one below the exit rank of SXXP. Forecasted passive fund supply is $11.5m and 1.4 ADV.</li>
<li>'Most liquid stock' criterion can cause a 'switch' of share lines in the index as it happened with <a href="https://www.smartkarma.com/entities/chocoladefabriken-lindt-spru-d0c11ab4-21ec-491e-9b8f-44b06e078529" target="_blank" data-smartkarma-citation="entities:24963:1" rel="noopener">Lindt (LISP SW)</a> and <a href="https://www.smartkarma.com/entities/chocoladefabriken-lindt-sprungli" target="_blank" data-smartkarma-citation="entities:22420:1" rel="noopener">Lindt (LISN SW)</a> in September 2022. </li>
</ul>



Koninklijke Vopak Nv (VPK NA) &amp; Shaftesbury PLC (SHB LN) are currently passing the entry rank of SXXP. Forecasted passive fund demands are $22m-$34m and 3-5 ADV. 

Indivior PLC (INDV LN) is currently the only one below the exit rank of SXXP. Forecasted passive fund supply is $11.5m and 1.4 ADV.
'Most liquid stock' criterion can cause a 'switch' of share lines in the index as it happened with Lindt (LISP SW) and Lindt (LISN SW) in September 2022. 


STOXX 600: First September Forecasts for Europe and Eurozone

Research from Hardman & Co, Hardman & Co

Hardman & Co

Research from Hardman & Co

Investment research on quoted companies and funds

Hardman & Co is a multi-disciplinary financial consultancy and investment research firm, employing highly experienced analysts and professionals with a broad range of capital markets expertise. Our clients are public and private businesses as well as fund managers, ranging from start-ups to £1 billion+ market capitalisations. Hardman & Co offers corporate research & consultancy, serving the needs of both public and private companies. We produce gold-standard research with a global reach for trading and investment companies, as well as providing market commentary and analysis. In addition, we carry out a number of bespoke investment-related assignments, including due diligence on bond listings, assessments of private company valuations and other corporate advisory services. We engage with the market through traditional and digital media, offering illuminating video content on corporate management strategy, results communication, interviews and in-house sector discussion.

Equity Bottom-Up

Oxford Nanopore Technologies / Equity Bottom-Up

<ul><li>Feature article: Hardman & Co Healthcare Index, 2024 – Tough year for Life Sciences By Dr Martin Hall The main function of the HHI is to monitor the performance, and to highlight the attractiveness, of life sciences investments over the long term, and to try to identify those stocks that have disruptive technologies that consistently allow them to outperform both the index and the markets.</li><li>Many of the 53 constituents of the index are high-risk, with micro-capitalisations and a long way from profitability.</li><li>Despite this, some companies can still make extremely attractive returns for investors.</li></ul>

Feature article: Hardman & Co Healthcare Index, 2024 – Tough year for Life Sciences By Dr Martin Hall The main function of the HHI is to monitor the performance, and to highlight the attractiveness, of life sciences investments over the long term, and to try to identify those stocks that have disruptive technologies that consistently allow them to outperform both the index and the markets.Many of the 53 constituents of the index are high-risk, with micro-capitalisations and a long way from profitability.Despite this, some companies can still make extremely attractive returns for investors.

Thematic (Sector/Industry)

<ul>
<li>The Hardman &amp; Co Healthcare Index (HHI) has been running since 2009.</li>
<li>Its main function is to highlight the attractions of life sciences investments over the long term.</li>
<li>For the third year running, despite generally good returns in global markets, particularly in the US, performance in 2024 was poor, not helped by the capital-intensive nature of the sector.</li>
</ul>


The Hardman &amp; Co Healthcare Index (HHI) has been running since 2009.
Its main function is to highlight the attractions of life sciences investments over the long term.
For the third year running, despite generally good returns in global markets, particularly in the US, performance in 2024 was poor, not helped by the capital-intensive nature of the sector.


Hardman & Co Healthcare Index: 2024 – Tough year for Life Sciences

Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

<ul><li>Indivior PLC presented its financial results for the third quarter of 2024, offering insights into the company's performance and strategic efforts.</li><li>Key highlights from the call pointed to a mix of achievements, challenges, and future initiatives.</li><li>On the positive side, Indivior reported a 13% increase in total net revenue year-over-year, amounting to $307 million for the third quarter.</li></ul>

Indivior PLC presented its financial results for the third quarter of 2024, offering insights into the company's performance and strategic efforts.Key highlights from the call pointed to a mix of achievements, challenges, and future initiatives.On the positive side, Indivior reported a 13% increase in total net revenue year-over-year, amounting to $307 million for the third quarter.

Is Indivior the Next Big Takeover Target? Acquisition Rumors and Oaktree's Ultimatum Fuel Interest!

Index Rebal Trades & Special Situations, Quiddity Advisors

Janaghan Jeyakumar, CFA

Index Rebal Trades & Special Situations

Quiddity Advisors

Pan-Asia Catalysts/Events

<ul>
<li>In this insight, we take a look at the names leading the race to become ADDs/DELs for the STOXX Europe 600 and EuroSTOXX Indices for the December 2022 Rebalance.</li>
<li>I expect at least two STOXX Europe 600 constituents involved in M&amp;A deals to get deleted in November 2022. There could be more in December 2022.</li>
<li>
<a href="https://www.smartkarma.com/entities/dr-ing-h-c-f-porsche-aktiengesellschaft" target="_blank" data-smartkarma-citation="entities:36343:1" rel="noopener">Porsche AG (P911 GR)</a> is currently the highest ranked non-constituent and is leading the race to become an intra-review add in November 2022.</li>
</ul>


In this insight, we take a look at the names leading the race to become ADDs/DELs for the STOXX Europe 600 and EuroSTOXX Indices for the December 2022 Rebalance.
I expect at least two STOXX Europe 600 constituents involved in M&amp;A deals to get deleted in November 2022. There could be more in December 2022.

Porsche AG (P911 GR) is currently the highest ranked non-constituent and is leading the race to become an intra-review add in November 2022.


STOXX Europe Quiddity Leaderboard Dec 22: Two Intra-Review Changes & Porsche Addition Likely In Nov

United Kingdom

Indivior PLC is headquartered in England. The Company's line of business includes the manufacturing, fabricating, or processing of drugs in pharmaceutical preparations for human or veterinary use.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Indivior PLC (INDV LN)

STOXX 600: First September Forecasts for Europe and Eurozone

Koninklijke Vopak & Shaftesbury PLC are currently the top 2 candidates for addition in SXXP while Indivior PLC is the main candidate for deletion.

Dimitris Ioannidis

Hardman & Co Monthly: January 2025

Feature article: Hardman & Co Healthcare Index, 2024 – Tough year for Life Sciences By Dr Martin Hall The main function of the HHI is to...

Hardman & Co

Hardman & Co Healthcare Index: 2024 – Tough year for Life Sciences

The Hardman & Co Healthcare Index (HHI) has been running since 2009. Its main function is to highlight the attractions of life sciences investments...

Hardman & Co

Is Indivior the Next Big Takeover Target? Acquisition Rumors and Oaktree's Ultimatum Fuel Interest!

Indivior PLC presented its financial results for the third quarter of 2024, offering insights into the company's performance and strategic...

Baptista Research

STOXX Europe Quiddity Leaderboard Dec 22: Two Intra-Review Changes & Porsche Addition Likely In Nov

Between now and the end of the year, there could up to 14 constituent changes in the STOXX Europe 600 index including 5 intra review changes....

Janaghan Jeyakumar, CFA

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

STOXX 600: First September Forecasts for Europe and Eurozone

​Koninklijke Vopak & Shaftesbury PLC are currently the top 2 candidates for addition in SXXP while Indivior PLC is the main candidate for deletion.

Dimitris Ioannidis

Hardman & Co Monthly: January 2025

Feature article: Hardman & Co Healthcare Index, 2024 – Tough year for Life Sciences By Dr Martin Hall The main function of the HHI is to...

Hardman & Co

Hardman & Co Healthcare Index: 2024 – Tough year for Life Sciences

The Hardman & Co Healthcare Index (HHI) has been running since 2009. Its main function is to highlight the attractions of life sciences investments...

Hardman & Co

Is Indivior the Next Big Takeover Target? Acquisition Rumors and Oaktree's Ultimatum Fuel Interest!

Indivior PLC presented its financial results for the third quarter of 2024, offering insights into the company's performance and strategic...

Baptista Research

STOXX Europe Quiddity Leaderboard Dec 22: Two Intra-Review Changes & Porsche Addition Likely In Nov

Between now and the end of the year, there could up to 14 constituent changes in the STOXX Europe 600 index including 5 intra review changes....

Janaghan Jeyakumar, CFA

Koninklijke Vopak & Shaftesbury PLC are currently the top 2 candidates for addition in SXXP while Indivior PLC is the main candidate for deletion.